Skip to main content

Table 1 Main characteristics, end points and outcomes of Sacubitril/Valsartan trials of non-oncologic patients with heart failurea

From: In ®Entresto we trust

Clinical trial

No. of patients

Follow-up (months)

End point

Event rate (%)

HR (95% CI)

P value

Intervention

Control

PARADIGM-HF

8442

27

All-cause mortality

17.0

19.8

0.84 (0.76–0.93)

<.001

  

CV death, HF hospitalization

21.8

26.5

0.80 (0.73–0.87)

<.001

  

HF hospitalization

12.8

15.6

0.81 (0.71–0.89)

<.001

PIONEER-HF

881

2

HF hospitalization

8.0

13.8

0.56 (0.37–0.84)

–

  

All-cause mortality

2.3

3.4

0.66 (0.30 to 1.48)

–

  

NT-proBNP reduction

46.7

25.3

0.71b (0.63–0.81)

< 0.001

TRANSITION

1002

2.5

Proportion of patients attaining 97/103 mg bid target dose after 10 weeks

45.4

50.7

0.90c (0.79–1.02)

0.099

PROVE-HF

654

12

Correlation between log2–NT-proBNP changes in patients treated with S/V and changes in measures of cardiac volume and function

LVEF (r = −0.381 [IQR, −0.448 to −0.310]; P < .001),

LVEDVI (r = 0.320 [IQR, 0.246 to 0.391]; P < .001), LVESVI (r = 0.405 [IQR, 0.335 to 0.470]; P < .001),

LAVI (r = 0.263 [IQR, 0.186 to 0.338]; P < .001),

E/e′ ratio (r = 0.269 [IQR, 0.182 to 0.353]; P < .001).

  1. CI confidence interval, CV cardiovascular, LAVI left atrial volume index, LVEDVI Left ventricle end-diastolic volume index, LVEF left ventricular ejection fraction, LVESVI Left ventricle end-systolic volume index, NT-proBNP N-terminal prohormone of brain natriuretic peptide, HF heart failure, HR hazard ratio, IQR interquartile range, MO months, PARADIGM-HF Prospective Comparison of ARNI with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure, PIONEER-HF Comparison of Sacubitril-Valsartan vs Enalapril on Effect on NT-proBNP in Patients Stabilized from an Acute Heart Failure Episode, PROVE-HF Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure, S/V Sacubitril/Valsartan, TRANSITION Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event
  2. aBased on references [2,3,4,5]
  3. bRatio of change
  4. cRisk ratio
Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us